Solid biosciences announces fda ind clearance for first-in-industry dual route of administration gene therapy to treat both neurologic and cardiac manifestations of friedreich's ataxia

- sgt-212 is the only full-length frataxin replacement gene therapy candidate targeting the cns and cardiac manifestations of friedreich's ataxia -

SLDB Ratings Summary

SLDB Quant Ranking